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Abstract 
  
The non-canonical Wnt pathway, a regulator of cellular motility and morphology, is increasingly 
implicated in cancer metastasis. In a quantitative PCR array analysis of 84 Wnt pathway associated 
genes, both non-canonical and canonical pathways were activated in primary and metastatic tumors 
relative to normal prostate. Expression of the Wnt target gene PITX2 in a prostate cancer (PCa) 
bone metastasis was strikingly elevated over normal prostate (over 2000 fold) and primary prostate 
cancer (over 200 fold). The elevation of PITX2 protein was also evident on tissue microarrays, with 
strong PITX2 immunostaining in PCa skeletal and, to a lesser degree, soft tissue metastases. PITX2 
is associated with cell proliferation and migration during normal tissue morphogenesis. Here, 
overexpression of individual PITX2A/B/C isoforms stimulated PC-3 PCa cell proliferation and 
motility, with the PITX2A isoform imparting a specific motility advantage in the presence of non-
canonical Wnt5a stimulation. Furthermore, PITX2 specific shRNA inhibited PC-3 cell migration 
toward bone cell derived chemoattractant. These experimental results support a pivotal role for 
PITX2A and non-canonical Wnt signaling in enhancement of PCa cell motility, suggest PITX2 
involvement in homing of PCa to the skeleton, and are consistent with a role for PITX2 in PCa 
metastasis to soft and bone tissues. Our findings, which significantly expand previous evidence that 
PITX2 is associated with risk of PCa biochemical recurrence, indicate that variation in PITX2 
expression accompanies and may promote prostate tumor progression and metastasis.  
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Introduction 
 
It is widely acknowledged that malignancy subverts biologic and developmental processes and 
pathways during cancer progression and metastasis. Pathways that normally act as tumor 
suppressors or biologic gatekeepers are transmuted to provide positive signals for cellular survival, 
proliferation or motility. One pathway increasingly described as having such duality of function in 
normal and malignant cells is the Wnt pathway, which denotes a set of related but functionally 
distinct canonical and non-canonical pathways. The canonical Wnt response is mediated via nuclear 
!-catenin transcriptional activity and has been implicated in both prostate cancer progression and 
control of normal bone function (1-4). The major non-canonical Wnt pathways are not !-catenin 
mediated (5), but instead involve planar cell polarity (PCP), calcium, Rho GTPases and JNK 
signaling (6-8). Recently, accumulating evidence implicates non-canonical Wnt signaling in the 
control of cellular movement during embryologic development and in cancer-related events such as 
epithelial to mesenchymal transition (EMT) and the metastatic process (7-9). 
 
The Wnt-associated gene PITX2, originally identified in the pituitary, encodes a transcription factor 
carrying a bicoid-related homeodomain (10). There are three major PITX2 protein isoforms in 
humans (10). PITX2A and PITX2B are translated from alternatively spliced transcripts originating 
from a promoter designated P2, whereas the PITX2C encoding transcript originates at an alternative 
upstream promoter, P1 (10, 11). Point mutations in this gene are responsible for the Axenfeld 
Rieger Syndrome, which is characterized by ocular, umbilical/body wall and cardiovascular 
abnormalities, tooth agenesis, and facial dysmorphism including cleft palate (11-13). In mice, 
PITX2 plays a role in the left-right determination of various structures such as gut and heart, and 
controls cellular migration and motility during this process (10, 14, 15). Consistent with clinical and 
experimental evidence for its involvement in tissue development, PITX2 has been observed to 
interact with the canonical Wnt (12, 16-20) and non-canonical Wnt (21, 22) pathways and also to 
act as a downstream effecter of developmental regulatory pathways involving Sonic Hedgehog, 
Lefty and Nodal (11, 13-15).  
 
Recent reports suggest that PITX2 might act as a tumor suppressor. Hypermethylation of the PITX2 
gene in primary PCa was associated with an increased risk of biochemical recurrence following 
primary therapy, potentially indicating a tumor suppressor role (23-25). Furthermore, PITX2 was 
also associated with increased risk of disease recurrence in node negative, hormone receptor 
positive, tamoxifen-treated breast cancer (26-31). In contrast to these reports, we present evidence 
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from both quantitative PCR array and immunohistochemistry analyses that PITX2 is elevated in 
Gleason score 3, albeit in a minority of samples, with a loss of expression at Gleason score 4 
followed by reappearance of considerable expression in metastatic samples, particularly in bone 
metastases. In light of this new information and given the human and mouse genetic evidence about 
PITX2 involvement in cell migration during development, we conducted a functional analysis to 
determine whether PITX2 may be directly involved in control of cellular motility in a prostate 
cancer cell line, specifically testing for roles in the non-canonical Wnt response and in bone cell-
directed migration. 
  
Material and methods 
 
Frozen tissue samples and PCR arrays 
 
All studies were carried out following approval by the local Human Ethics Review Panel with 
consented patients at the Princess Alexandra Hospital (Brisbane, Australia) providing specimens. 
The qRT-PCR Wnt array study used fresh and fresh frozen archived human prostate normal and 
primary PCa specimens obtained either at radical prostatectomy, transrectal ultrasound guided 
biopsy or transurethral resection of the prostate. In addition, one fresh clinical human PCa bone 
metastasis was obtained with patient consent at time of elective orthopedic fixation of an impending 
pathologic fracture of the femur. Trizol reagent RNA extraction from fresh frozen tissue was 
performed with further purification using the RNeasy Minikit including DNase I treatment 
(Qiagen).  
 
Wnt pathway related gene expression was quantitatively assessed using the RT2 Profiler PCR Wnt 
Pathway Array System (SA Bioscience). Real time PCR analysis was performed using Sybr Green 
technology (ABI 7300 Thermal Cycler, Applied Biosystems). Array data were normalized to 
housekeeping genes utilising the "Ct method and analyzed statistically by one-way analysis of 
variance followed by Student’s T-test using the spreadsheet provided by SA Bioscience at 
http://www.sabiosciences.com/pcrarraydataanalysis.php. 
 
 
Clinical tissue microarrays and immunohistochemistry (IHC) 
 
Human tissue microarrays (TMA) of fixed paraffin embedded primary and metastatic PCa tissues 
were obtained as part of the University of Washington (UW) PCa Research Program and the UW 
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Medical Center PCa Donor Rapid Autopsy Program, as approved by the UW Institutional Review 
Board with written informed consent obtained for all patients. Radical prostatectomy TMA series 
consisted of cores taken from 47 total patients; 67 cores of non-neoplastic prostate (from 24 
patients), 61 cores of Gleason score 3 (from 27 patients), and 44 cores of Gleason score 4 PCa 
(from 18 patients). The PCa metastases were obtained from 42 patients participating in the Prostate 
Cancer Donor Rapid Autopsy Program (32). The PCa metastasis array consisted of 90 soft tissue 
cores (24 patients) and 141 bone cores (24 patients). Five-µm sections of TMAs were stained with 
either H&E or by IHC using a protocol we have described previously (33), using antibodies against 
PSA 1:30,000 (Dako) or P2R10 for PITX2 1:100-200 (Capra Bioscience, Angelholm, Sweden) 
after pH 6 antigen retrieval (Dako). The P2R10 antibody recognizes all known PITX2 protein 
isoforms except PITX2D (34). 
 
 
Cell lines and cultures 
 
PC-3 prostate cancer and SaOS-2 osteosarcoma human cell lines, the mouse fibroblastic L cell and 
Wnt5a over-expressing L cell lines were obtained from the American Type Culture Collection 
(ATCC) and cultured in appropriate growth media. SaOS-2 conditioned media (CM) was prepared 
from confluent monolayers cultured for 48 h in serum free DMEM, sterile filtered (0.22 µm) and 
stored at 4˚C. Conditioned media from L cell and Wnt5a over-expressing cell lines (L-CM and 
Wnt5a-CM) were produced as per ATCC instructions. Co-culture experiments to assess osteoblast 
effects on PITX2 expression in PCa cells were conducted in experimental medium (ExpM) 
consisting of 50% DMEM and 50% RPMI plus 1% FBS and 1% P/S using transwell inserts (0.4 
µM pore) in 6 well plates (BD Biosciences). SaOS-2 cells were seeded in the bottom well (1 x 
104/cm2) and PC-3 cells were seeded in the insert (1 x 104/cm2) cultured separately for 48 h in 
standard growth media containing 10% FBS prior to bringing the two co-culture components 
together in the ExpM. PC-3 cells were collected from the insert 48 h later for RNA preparation. 
 
 
Plasmids and transient transfection of PC-3 cells 
 
Plasmids for over expression of individual PITX2 isoforms (human cDNA clones of transcript 
variants 1 (NM_153427), 2 (NM_153426) and 3 (NM_000325)) in a MYC- and FLAG-tagged 
pCMV6 entry vector were purchased from Origene (TrueORF, Origene Technologies). PITX2 
specific shRNA plasmids targeting all three variants (Sure Silencing Plasmids, SA Bioscience) were 
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screened for ability to reduce production of all three PITX2 isoforms (Fig S.1); the SH3, SH4 and 
negative control (NC) plasmids were chosen for subsequent studies (Table 1). PC-3 cells were 
transfected with shRNA or expression plasmids using Lipofectamine 2000 (Invitrogen). Co-
transfection of each PITX2 isoform plasmid (0.5 µg) with each shRNA plasmid (0.5 µg) was used 
to validate individual isoform effects on cell motility in scratch assays.  
 
 
Proliferation and viable cell assays 
 
BrdU cell proliferation ELISA (Roche) was performed to assess effects of PITX2 over expression 
or knockdown on PC-3 cell proliferation. In separate experiments, changes in cell number were 
estimated by Syto 60 assay to assess effects of transient PITX2 over expression or knockdown in 
PC-3 cells. Results were analyzed using the plug-in Odyssey software following scanning on the 
Odyssey Infrared scanner (LI-COR Biosciences). 
 
 
Scratch motility assay 
 
Effects of PITX2 over expression or knockdown on PC-3 cell motility were analyzed using a 
scratch or wound-healing assay. Cells were seeded in externally marked 6 well plates (5.25 x 
104/cm2), transfected in serum free RPMI, cultured a further 24 h, then treated for 5 h with 
mitomycin C (15 µg/ml) prior to scratching, washing in PBS and refeeding of the confluent 
monolayers. Wells were imaged at 0, 4, 8, 12 and 24 h post scratch using external reference lines to 
ensure reproducibility. Images were analyzed using Image J software (NIH) with closure of the 
scratch calculated as a percentage of the original wound area over time. To assess PITX2 
involvement in the non-canonical Wnt response, scratch motility assays were performed on 
transfected cultures with PITX2 over expression or knockdown, initially in RPMI culture medium 
supplemented with 10% L-CM or 10% Wnt 5a-CM, and subsequently in serum free RPMI 
supplemented with purified recombinant Wnt 5a protein (50 ng/ml) (R&D Systems).  
 
 
Transwell migration assay 
 
Migration assays were also performed in 12 well cell culture inserts with 8 µm pores (BD 
Biosciences). PC-3 cells were transfected with shRNA plasmids in the absence of FBS as described 
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for scratch assays. After 24 h transfected cells were seeded into the well insert (5.25 x 104/cm2) in 
serum free medium plus 0.1% BSA (Sigma) and at 5.25 x 104/cm2 in 200 µL of serum free medium 
plus 0.1% BSA (Sigma). The seeded inserts were subsequently placed into wells containing culture 
medium supplemented with 10% FBS or 10% SaOS-2 CM. Mock transfected (control) cells in 
inserts above medium containing 0% FBS were used to establish a baseline level of random 
migration. Cell migration was assessed after 12 h incubation by the standard crystal violet 
quantification procedure and normalized back to serum free control levels (35). 
 
 
Quantitative reverse transcription polymerase chain reaction 
 
First strand cDNA synthesis for qRT-PCR was performed using the Superscript III First-Strand 
Synthesis System (Invitrogen). Specific transcript levels were analyzed on the Rotor-gene RG-6000 
thermocycler (Corbett Research, Sydney) or ABI 7900HT Thermal cycler (Applied Biosystems). 
All primers were designed using Primer 3 software (36). 
 
Statistics 
 
Data analysis was performed using Microsoft Excel 2007 (Microsoft Corp, Redmond, WA, USA) 
and R version 2.7.2, pgirmess library (Team RDC, Vienna, Austria). Data were analyzed using 
ANOVA and the Student’s T test to evaluate the significance of the difference in mean values 
between cell lines, treatments and specimens.  P values <0.05 were considered to indicate 
statistically significant differences. Data are represented as mean ± standard error (SE) unless 
otherwise stated. 
 
To compare the staining profile of PITX2 in the nucleus and cytoplasm of the primary prostate and 
PCa metastases, GEE regression was used, keeping track that cores from a same site of a same 
patient tend to be more closely correlated with each other than others. The GEE regression model 
used: 
Model   E(Scorei) = 1.32 # 0.44Ni # 0.5SOFTi, 
95% Confidence interval        (#0.69,#0.19)   (#0.71,#0.3) 
where Ni = 1 if tissue from nucl, 0 else; SOFTi = 1 if tissue from soft tissues, 0 else. The baseline 
group is cytoplasm staining of tissue from bone. 
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Results 
 
In an initial investigation of altered expression of Wnt pathway genes in prostate tumor tissues at 
various stages of cancer progression, transcript abundance levels were profiled in a small number of 
archived and fresh frozen tissue samples using quantitative RT-PCR arrays. Multiple differences in 
Wnt pathway and associated gene expression levels (at least 2 fold change) were noted between 
specimens of normal (benign) prostate (n = 2) and malignant prostate (n = 9). Interestingly, data for 
a single available PCa bone metastasis suggested that these changes might even be increased in 
metastasis vs primary PCa. Analyses of these changes indicated that similar sets of genes were 
altered in primary and metastatic PCa compared to normal prostate, with the number and magnitude 
of changes greater in metastatic disease. Specifically, cellular growth, proliferation and cell 
survival/viability pathways were increased whereas genes involved with apoptosis and 
differentiation were down regulated in malignant tissues; in metastatic disease a strong increase in 
genes involved in cellular motility was also noted (Table S.1). 
 
One of the large, consistent changes we detected in our preliminary analysis was alteration of 
PITX2 expression, with marked differences among normal, primary cancer and metastatic cancer 
samples in terms of both fold change and P value (Fig. 1A). PITX2 expression in the bone 
metastatic deposit exceeded the mean levels in normal prostate by 2252 fold and in primary PCa by 
227 fold. The array results were confirmed by gene-specific qPCR analysis using universal PITX2 
primers, which amplify transcripts encoding the three major PITX2 isoforms (Fig. 1B). Total 
PITX2 transcripts were 5 fold higher in primary tumor samples and over 1000 fold higher in the 
bone metastatic specimen compared to normal prostate tissue.  
 
These preliminary analyses were of total tissue extracts, which would be affected by the cellular 
composition and proportion of stroma to cancer in each sample. Nevertheless the data suggested a 
potential role for PITX2 in PCa progression. To explore this possibility, an investigation of PITX2 
protein patterns in early stages of PCa was conducted by immunohistochemistry staining of a TMA 
composed of samples from normal (benign) prostate, primary PCa Gleason score 3 and score 4 (Fig. 
2). Although PITX2 functions as a nuclear transcription factor, our analysis did not reveal any 
significant differences in nuclear PITX2 immunoreactivity when normal prostate, Gleason score 3 
and Gleason score 4 samples were compared. In all of these samples we detected only a few nuclei 
with intense immunoreactivity, while at least 75% of nuclei were negative (Fig. 2A). In comparison, 
there was evidence that cytoplasmic staining was significantly different between benign, Gleason 
score 3 and Gleason score 4 specimens (p= 0.025), with the average cytoplasmic staining score in 
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Gleason score 3 cores estimated to be 0.11 higher than in benign cores (95% confidence interval, -
0.08 to 0.32). In contrast, cytoplasmic staining was reduced in cores from Gleason score 4 tumors, 
estimated to be -0.19 lower than scores for benign cores (95% confidence interval -0.39 to 002) and 
-0.30 lower than Gleason score 3 cores (95% confidence interval -0.50 to -0.10). Representative 
histological sections show the nuclear and cytoplasmic staining observed in these specimens (Fig. 
2B).  
 
Next, given our finding of >1000-fold elevation of PITX2 expression in the single bone metastasis 
sample of the PCR array analysis, we extended our investigations to more advanced stages of the 
disease by evaluation of PITX2 immunoreactivity using a TMA consisting of a large cohort of 
matched bone and soft tissue metastases. These metastatic samples were from 24 different patients 
and totaled 141 bone cores and 90 soft tissue cores, the latter including lymph nodes, liver and other 
non-skeletal metastases. Of an original 256 cores, a total of 231 were scored for PITX2 staining in 
both nucleus and cytoplasm as 25 cores either had no cancer cells or sections were lost from slides 
(9.8%). Representative sections show the generally increased PITX2 signal observed in the bone 
metastases compared to soft tissue metastases (Fig. 3B).  
 
Variation in PITX2 expression profile was specifically assessed between bone metastases and soft 
tissue metastases (Fig. 3A). Our analysis suggests that the nuclear staining score of soft tissues 
(liver, lymph node and other soft tissues) is different from bone (p=0.02) with the average soft 
tissue score estimated to be -0.26 lower than that of bone (95% confidence interval, -0.48 to -0.05). 
Despite notable diversity between patients, there is strong evidence that the staining score in bone 
metastases was greater than the score for metastases in soft tissues (p<0.01), with the score for soft 
tissue metastases estimated to be -0.5 lower than that for bone metastases (95% confidence interval, 
-0.71 to -0.3). For cytoplasmic staining, there is strong evidence that the staining score of soft 
tissues (liver, lymph node and other soft tissues) is different from bone (p=0.01), with the average 
score of soft tissue estimated to be -0.74 lower than that of bone (95% confidence interval, -1.01 to 
-0.48) 
 
Although cytoplasmic staining has previously been observed, the functional significance of this 
distribution is not known. Variation in nuclear and cytoplasmic staining patterns could potentially 
relate to differences in PITX2 isoform expression profile. To explore this concept, individual levels 
of transcripts encoding each isoform as well as total PITX2 transcripts were assessed in the clinical 
specimens previously interrogated on PCR transcript arrays. Consistent with the earlier findings 
(Fig. 1) total PITX2 transcript levels in tumor samples were elevated compared to normal prostate, 
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and transcript levels of individual isoforms also rose incrementally from normal prostate tissue, to 
primary cancer, to metastasis (Table 3). Specifically, PITX2A transcripts were not detectable in 
normal tissue but were present at a fairly low level in primary tumors and elevated over 1500 fold in 
the bone metastasis sample compared to the primary tumors. Likewise, levels of PITX2B and 
PITX2C transcripts were low in normal tissue, elevated somewhat in primary tumors, and markedly 
elevated (2500 and 4200 fold, respectively) in the bone metastatic deposit.  
 
These consistent indications from both mRNA and protein analyses that PITX2 expression was 
higher in more advanced cancers led us to investigate its involvement in characteristic cellular 
functions that are altered in metastatic cancer cells. A role for PITX2 in cell proliferation and 
migration was therefore tested in the PC-3 PCa cell line, which expresses a low level of endogenous 
transcripts encoding each of the three PITX2 isoforms. In tests using over-expression of individual 
PITX2 isoforms, cell proliferation increased significantly in cells transiently over expressing any 
one of the three isoforms (Fig. 4A). In contrast, effects of isoform over expression on cell number 
were less uniform, with PITX2A over expression causing an increase in cell number but PITX2C 
transfection leading to a modest but significant decline in cell number (Fig. 4C). Knockdown of all 
PITX2 isoforms, however, did not significantly alter cell proliferation or number (Fig. 4B, D) 
despite evidence that each PITX2-specific shRNA construct can effect a knockdown of at least 25% 
for all PITX2 isoforms in the PC-3 cell line (Fig. S.1). Together, these over expression and 
knockdown studies indicated that all three PITX2 isoforms have modest but positive effects on cell 
proliferation and mixed effects on cell number.  
 
The effect of increasing levels of individual PITX2 isoforms on cell migration was assessed using 
scratch wound healing assays in non-proliferating (mitomycin C treated) PC-3 cultures. Over 
expression of any single PITX2 isoform significantly increased cellular motility compared to 
control cultures (Fig. 5A). Conversely, knockdown of endogenous PITX2 significantly decreased 
cellular motility, with both gene-specific shRNA constructs reducing wound closure compared to 
the negative control shRNA (Fig. 5B). Knockdown of individual over-expressed isoforms by co-
transfection with shRNA constructs validated these results (Fig. 5C-E). Together these findings 
strongly support a role for PITX2 in promotion of cellular motility in PC-3 PCa cells. 
 
Given prior evidence of PITX2 involvement in cell migration during development (14, 15, 37) and 
PITX2 interactions with both Wnt pathways (12, 17-19, 38), as well as of non-canonical Wnt 
involvement in cellular motility and EMT, a potential interaction between PITX2 and non-canonical 
Wnt in regulating cancer cell motility was investigated in PC-3 PCa cells, which secrete high 
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baseline levels of the canonical Wnt antagonist DKK1 (2). In the scratch wound closure assay, the 
motility of PC-3 cells exposed to Wnt5a-CM for 24 h was increased by 30% (p=0.038) compared to 
cultures treated with control L-CM (Fig. 6A, grey vs white circles). This stimulatory effect of 
Wnt5a-CM was evident at earlier time points (t= 4 h and thereafter, grey vs white diamonds) in 
cultures transfected with the negative control NC shRNA plasmid (e.g., 50% increase at 24 h, 
p=0.0008) in spite of a general decrease in wound closure in the transfected control cultures. PITX2 
involvement in the Wnt5A-associated motility increase was confirmed by knockdown of cellular 
PITX2, with transfection of the SH4 construct abolishing the motility increase observed with 
Wnt5a-CM treatment observed in the NC cultures (grey vs white triangles). Transfection with the 
SH3 construct yielded similar results (data not shown). The specificity of the Wnt5a effect was 
confirmed in cultures treated with purified recombinant Wnt5a protein (Fig. 6B). Together these 
data support a critical role for PITX2 in the motility changes associated with Wnt5a induction of 
non-canonical Wnt pathway activation.  
 
To investigate roles of individual PITX2 isoforms in the non-canonical Wnt motility effects, 
transient over expression of individual isoforms and a wound healing scratch assay in the presence 
of Wnt5a-CM were performed. Over expression of PITX2A significantly increased PC-3 cell 
motility in Wnt5a-CM treated cultures (Fig. 6C, grey vs white squares). By contrast, in the empty 
vector control cells the increase in motility after Wnt5a-CM treatment was more modest and 
reached statistical significance only at the 24 h time point (grey vs white circles). In PITX2B or 
PITX2C over expressing cells (grey vs white triangles and diamonds, respectively), no further 
increases in motility were observed after Wnt5a-CM treatment. Thus, our data suggest that PITX2A 
is responsible for the effects on migration, while PITX2B and PITX2C do not appear to be directly 
involved in the non-canonical Wnt signaling effects on cellular motility. 
 
Given the high levels of PITX2 expression in the bone metastases, the possibility that PITX2 
expression in cancer cells is subject to paracrine regulation by the bone environment was 
investigated through trans-well co-culture experiments with human osteoblastic SaOS-2 cells. 
PITX2 transcription in PC-3 cells grown in the presence of the SaOS-2 culture was at least 3-fold 
higher than in control PC-3 cultures (Fig. 7A), indicating that SaOS-2 cells secrete a soluble 
factor(s) that stimulates PITX2 expression in cancer cells. This result suggests that PITX2 may be 
an active participant in the interaction between metastatic PCa cells and target skeletal tissue. 
 
To test whether PITX2 may be involved in homing of cancer cells to bone, we assessed PC-3 cell 
migration toward osteoblastic SaOS-2 conditioned medium using PITX2 knockdown. The 
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chemotactic response by cancer cells transfected with either SH3 or SH4 plasmid was significantly 
reduced (by 59% or 92% respectively) relative to cultures transfected with the NC shRNA (Fig. 7B, 
black bars). In contrast, transfection of either gene-specific or negative control shRNA plasmid did 
not significantly affect the migratory response to medium supplemented with FBS (Fig. 7B, white 
bars). These results are in agreement with those from the scratch motility assay analysis and also 
support a positive role for PITX2 in migration of the PC-3 cancer cells, particularly toward soluble 
factors produced by bone cells in vitro. 
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Discussion 
 
PITX2 has previously been investigated in prostate cancer. Hypermethylation of the gene in 
primary PCa was an independent prognostic indicator for biochemical recurrence (23, 25, 39) and 
predictive of increased risk of local recurrence in a stratified patient cohort (24). Promoter 
hypermethylation has also been associated with reduced PITX2 transcription in primary tumors 
(39). To a certain extent our immunohistochemistry analysis of early PCa samples is concordant 
with those published epigenetic findings, showing decreased levels of PITX2 protein in malignant 
versus normal prostate. Conversely, however, our analysis of advanced disease in prostate cancer 
metastases detected increased PITX2 levels, indicating re-expression of this highly methylated gene 
during cancer progression. We also observed higher levels of PITX2 protein in bone vs soft tissue 
metastases, which suggests that advanced PCa progression in the skeleton may occur through 
altered regulation of PITX2 expression and function caused by crosstalk between tumor cells and 
the bone microenvironment. Results of our in vitro investigations into mechanism support this 
possibility with evidence that a factor(s) secreted by osteoblastic cells stimulated PITX2 gene 
expression and was chemotactic for PCa cell migration. Our investigations further suggest a specific 
functional interaction between non-canonical Wnt pathway activity and the PITX2A isoform.  
 
PITX2 is a homeodomain-containing transcription factor. Our immunostaining data clearly show 
increased nuclear PITX2 signal in bone metastasis, again substantiating a claim of its involvement 
in bone metastasis progression. In addition, the strong cytoplasmic staining clearly indicates that the 
PITX2 gene promoter is not hypermethylated in these patient samples, especially in the bone 
metastases. This altered staining may reflect a specific change of PITX2 function secondary to 
metastatic niche interactions. The data from the SaOS-2 osteoblastic co-culture and conditioned 
media experiments (discussed further below) suggest that this differential subcellular distribution 
and level of PITX2 could be indicative of particular isoform interactions with secreted osteoblast-
derived factors. Because the antibody used in this study does not distinguish between the major 
PITX2 isoforms (34) however, it is not possible to discern from our data whether the levels of 
individual protein isoforms change differentially with PCa progression.  
 
To gain insight into the roles of the PITX2 isoforms in PCa we analyzed levels of the individual 
isoform-encoding transcripts in a small subgroup of clinical samples. The PITX2A transcript was 
detected only in malignant tissue and not in normal prostate specimens whereas PITC2B and C 
transcripts were detected in all samples. In both normal and malignant prostate, the PITX2B 
transcript was expressed at a higher level than either A or C, making PITX2B the major expressed 
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isoform in this sample set. The differential expression of the A and B isoforms is interesting as both 
transcripts arise from the P2 promoter of the PITX2 gene (10, 34), far upstream of the P1 promoter 
region (51) which was the focus of the previous hypermethylation studies (25). Although the 
various PITX2 isoforms have been studied in normal development (12, 15, 16, 40, 41) and relative 
levels of isoform-specific transcripts have been seen to vary between tissues (34), our results 
showing expression of PITX2B and C in the absence of PITX2A transcripts in normal but not 
malignant prostate is to our knowledge the first observation of this pattern in any tissue. The 
manifestation of the pattern in the present context suggests a particular role for PITX2A in prostate 
malignancy.  
 
Our functional analyses in cultured PC-3 cells support significant roles for all three PITX2 isoforms 
in control of PCa cells, with both similarities and differences between the isoforms detected. Over 
expression of any of the three isoforms increased PC-3 cell proliferation modestly but significantly. 
A similar stimulatory effect of over expressed PITX2A on cell proliferation has also been observed 
in ovarian cancer cells (42), likely associated with activation of the Wnt/!-catenin pathway which 
was induced in ovarian cancer cells by all three PITX2 isoforms in vitro (43). Our experiments in 
PC-3 PCa cells did not investigate potential PITX2 involvement with canonical Wnt regulation in 
PCa, however, because this cell line produces a high level of Dkk1, a secreted antagonist of 
canonical Wnt activation (2). In contrast to the uniform stimulatory effects of the three isoforms on 
PC-3 proliferation, the PITX2 isoform effects on cell number varied. Over expressed PITX2A 
increased but PITX2C decreased viable cell numbers, highlighting the potential for PITX2 
involvement in PCa cell survival or apoptosis. In concept, this divergence between effects of the 
isoforms on cell proliferation and number in cancer cells is compatible with PITX2 involvement in 
multiple aspects of organogenesis and development including cell proliferation, differentiation, 
motility and apoptosis (14, 17, 44-46).  
 
In the scratch wound healing assays, each individual PITX2 isoform significantly increased cellular 
motility when over-expressed in PC-3 cells, but a difference between the isoforms emerged with 
concurrent non-canonical Wnt activation which uniquely enhanced the PITX2A stimulatory effect 
on motility. Thus far there is limited literature in this area (37), but it is feasible that Rho GTPase 
family (47) or ATF/CREB (21) signaling may be involved in interactions between PITX2A and 
non-canonical Wnt. In contrast, the absence of a non-canonical Wnt effect on the PITX2B and C 
isoform responses indicates interaction with other signaling pathway(s) associated with cell 
motility. Given frequent evidence for interactions between PITX2 and TGF ! superfamily members 
(21, 48-50) and in light of the chemotactic response of PC-3 cells to SaOS-2 secreted factor(s), a 
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likely possibility is involvement of TGF ! or bone morphogenetic proteins (BMPs), which are both 
abundant in bone matrix. Upon its release by bone resorption in the initial stages of skeletal 
metastases, TGF ! is thought to provide multiple cancer promoting signals that enhance bone 
resorption and lead to further liberation of growth factors. Given the importance of Wnt signaling in 
adult bone tissues (2), it seems likely that PITX2 may play an integrative role between Wnt and 
TGF ! pathways in PCa bone metastasis. Our evidence that PITX2 expression in PC-3 cells was 
stimulated by an osteoblast secreted factor(s) suggests a scenario in which PITX2 may play a 
central role in synergistic interactions between bone and cancer cells in late stage PCa bone 
metastasis. 
 
No documented increase in cancer formation has been observed in patients with Axenfeld Rieger 
syndrome, in which loss of function mutation of the PITX2 gene leads to developmental 
abnormalities. This argues against a potential role for PITX2 solely as a tumour suppressor gene. In 
light of this lack of genetic association as well as recent evidence that elevated PITX2 expression 
occurs in other carcinomas (42, 43, 45, 52) and given the results of our study, it now appears that 
the literature associating PITX2 hypermethylation with a higher risk of prostate and breast cancer 
recurrence (23-25, 28-31, 53-56) may be a partial account of the complex involvement of PITX2 in 
these cancers. There is precedent that other cancer-associated pathways act as both tumor 
suppressors and promoters depending on their temporal activation. In the context of the preceding 
discussion, a notable example is the TGF ! pathway which can have tumor suppressor effects early 
in cancer progression but promote metastasis and tumor growth in later disease (57, 58). PITX2 
may exhibit a similar duality of function, acting as a tumor suppressor early in disease (consistent 
with hypermethylation as a negative prognostic event for progression) and subsequently providing 
tumor and metastasis promoting facilities including interaction with the metastatic 
microenvironment in bone and potentially other Wnt regulated tissues.  
 
Conclusion 
 
The research presented here provides preliminary evidence for involvement of PITX2 in prostate 
cancer progression and metastasis. Clinically and experimentally PITX2 shows potential as a factor 
involved in the promotion of the metastatic phenotype and as a novel therapeutic target. The 
applicability of PITX2 to these areas mandates further investigation. 
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Table 1. Short hairpin RNA plasmids 
Clone ID Insert Sequence 
shRNA clone 3 (SH3) GTCTCAACAGCCTGAATAACT 
shRNA clone 4 (SH4) GACATGTCCACACGCGAAGAA 
Negative control (NC) GGAATCTCATTCGATGCATAC 
Purchased shRNA plasmids and sequences of their inserts, in 5’ to 3’ orientation.  
 
 
 
 
Table 2. Primer pairs for quantitative polymerase chain reaction. 
Gene Primer Sequence Forward Primer Sequence Reverse 
PITX2 (U) CAGCCTGAGACTGAAAGCA GCCCACGACCTTCTAGCAT 
PITXA GCGTGTGTGCAATTAGAGAAAG CCGAAGCCATTCTTGCATAG 
PITXB GCCGTTGAATGTCTCTTCTC CCTTTGCCGCTTCTTCTTAG 
PITXC ACTTTCCGTCTCCGGACTTT CGCGACGCTCTACTAGTCGTCCT 
Housekeeping gene 
Cyclophilin  GCCGATGACGAGCCCTTGGGCC ACCAGTGCCATTATGGCGTGTG 
Sequences of primer sets for quantitative real time PCR, all in 5’ to 3’ orientation. The 
universal primer set (U) recognizes all three PITX2 isoforms. 
Table 3. PITX2 transcript levels in clinical specimens. 
Sample PITX2 PITX2A PITX2B PITX2C 
Normal Prostate (n=2) 8.4E-04 0 2.7E-05 1.6E-06 
Primary Prostate Cancer (n=9) 3.4E-03 2.2E-05 6.8E-05 2.0E-05 
Prostate Cancer Bone Metastasis (n=1) 9.6E-01 3.5E-02 1.7E-01 8.4E-02 
Levels of PITX2 encoding transcripts in clinical tissue samples as assessed using 
quantitative PCR with Universal and isoform-specific primers, values normalized to the 
cyclophilin housekeeping gene.  
 
 
Figure 1. PITX2 expression levels in clinical prostate tissue and tumor specimens. (A) 
Data from qPCR array, normalized to housekeeping gene expression. #p<0.001, 
##p<0.0005, difference vs metastatic sample. (B) Independent confirmation of array 
results using the PITX2 universal primer pair for qPCR analysis.  Mean values for cancer 
samples were normalized to mean value for normal prostate tissue. *p<0.05 vs normal 
prostate.  All values are mean ± S.D. of clinical samples.  
 
 
Figure 2: Tissue microarray analysis of PITX2 in benign prostate tissue and primary 
tumors. Profiles of PITX2 nuclear and cytoplasmic staining intensities (A), and 
representative examples of PITX2 staining (B) in benign (normal) prostate, and primary 
prostate cancer Gleason scores 3 and 4. Magnification x200. 
 
 
Figure 3: Comparison of PITX2 cytoplasmic and nuclear staining profiles for bone and 
soft tissue metastases. (A) There is strong evidence that staining score of soft tissues 
(liver, lymph node and others) is lower than bone scores. See text for statistical details. 
(B) Tissue microarray examples stained for PITX2 protein. Generally more intense signal 
was seen in the metastatic samples compared to the primary prostate in Figure 2 with 
bone metastases exhibiting stronger signal compared to the soft tissue metastases. 
 
 
Figure 4: Changes in cell proliferation and number with altered PITX2. PC-3 cells 
transiently transfected with PITX2 isoform-specific expression vectors (A, C) or shRNA 
plasmid (B, D) and assayed after 48 h for incorporation of BrdU to measure cell 
proliferation (A, B) or Syto 60 to assess viable cells (C, D). Bars show normalized 
absorbance from respective assays, mean ± SE. Significance *p<0.05, **p<0.01, 
***p<0.001 vs empty vector (Vector) or NC control as relevant. N= 12 wells /condition.      
 
 Figure 5: PITX2 over expression promotes cancer cell migration.  (A) Effects of 
individual PITX2 isoform over expression on cellular motility as assessed by scratch 
assay closure in mitomycin C-treated PC-3 cultures. (B) Effects of knocking down 
endogenous PITX2 using two gene-specific shRNA constructs (SH3, SH4) or nonspecific 
control (NC).  (C-E) Knockdown of individually overexpressed PITX2 isoforms 
confirms specificity of the effects on motility. Grey symbols indicate individual isoform 
vector (specified in legend) co-transfected with NC plasmid. White symbols denote co-
transfection with particular shRNA construct as indicated in panel B. Data are mean±SE; 
significance *p<0.05, **p<0.005, ***p<0.0005 vs mean value at the same time point post 
scratch (X-axis) for control samples (A,B) or for single isoform co-transfected with NC 
plasmid (C-E). Y axis indicates % wound closure in all panels.  
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 Figure 6.  Effects of PITX2 knockdown or over expression on scratch wound closure in 
presence of Wnt5a. In vitro assay of cell migration in PC-3 monolayer cultures, 
transiently transfected with shRNA constructs, without (A, B) or with (C) individual 
PITX2 isoform expression constructs. Transfected monolayers were treated with 
mitomycin C, scratches were applied and cultures were supplemented with conditioned 
medium (CM) from Wnt5a-transfected (5aCM) or control L cells (A, C), or recombinant 
Wnt 5a protein (50 ng/ml) (B). L-CM from control L cells or 5aCM from Wnt5a-
expressing L cells; SH4, PITX2-specific or NC, negative control shRNA; Wnt5a, 
recombinant Wnt5a protein. White and grey symbols denote L-CM and 5aCM (A, C) or 
No Wnt5a and recombinant Wnt5a (B) treatments respectively, as indicated. *p<0.05; 
**p<0.01; ***p<0.001, #p<0.0005, ##p<0.00005, vs L-CM (A, C) or vehicle (B) treated 
cultures at same time point. Y axis indicates % wound closure; note scale change in panel 
C.  
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Figure 7.  PITX2 implicated in the PC-3 motility response to osteoblast-conditioned 
medium.  (A) PITX2 expression in PC-3 cells was increased after 48 h co-culture with 
SaOS-2 osteoblastic cells. PITX2 transcripts normalized to cyclophilin expression using 
the PITX2 universal primer set; **p= 0.01, significant difference vs PC-3/FBS controls. 
(B) PC-3 migration toward osteoblastic chemoattractant(s) was decreased by PITX2 
knockdown with SH3 or SH4 (gene specific) vs NC negative control shRNA plasmid. 
Increase in motility of transfected cells toward control medium (10% FBS, white bars) or 
osteoblast-conditioned medium (10% SaOS-2 CM, black bars) relative to control cultures 
(mock transfected then exposed to 0% FBS, baseline). *p<0.05, ***p<0.001, difference 
vs NC transfected cultures of the same group. Values are mean±SE.  
 
Primary CaP /Normal 
Prostate 
Hu CaP MET/Normal 
Prostate 
  
Fold 
Difference 
P value Fold 
Difference 
P value 
Transcription Factors 
PITX2 10.20 
 
0.0634 
 
2252.14 0.0005 
 
T 3.47 0.3847 
 
4.33 0.0175 
 
MYC 2.42 0.2726 
 
3.74 0.0204 
 
LEF1 2.26 0.2120 
 
3.23 0.1539 
 
FOSL1 2.02 0.4169 
 
12.48 0.1405 
 
TLE1 2.02 0.4056 
 
4.68 0.0613 
 
FOXN1 1.36 0.7901 
 
-4.08 0.0270 
 
SOX17 1.28 0.6944 
 
3.24 0.1175 
 
EP300 1.21 0.6796 
 
-1.22 0.1244 
 
CTNNB1 -1.12 0.8053 
 
-1.30 0.1834 
 
TCF7 -1.17 0.8082 
 
-1.72 0.1982 
 
PYGO1 -1.27 0.6571 
 
2.14 0.0565 
 
JUN -1.27 0.7644 
 
3.88 0.0389 
 
CCND2 -1.31 0.7349 
 
-1.36 0.4350 
 
CCND1 -1.37 0.6320 
 
-3.96 0.0507 
 
TLE2 -1.47 0.6056 
 
-1.35 0.2441 
 
CCND3 -1.68 0.3794 
 
-1.70 0.3490 
 
CSNK1A1 -2.10 0.2129 
 
-2.80 0.0153 
 
Signal Transduction Factors 
APC -1.59 0.4446 
 
1.28 0.4787 
 
FZD8 2.64 0.1541 
 
3.37 0.0302 
 
FZD7 1.49 0.6569 
 
1.24 0.4922 
 
DVL1 1.18 0.6811 
 
4.06 0.0019 
 
FZD2 1.11 0.9021 
 
-4.89 0.1323 
 
FZD3 -1.06 0.9218 
 
-1.93 0.0748 
 
LRP5 -1.09 0.8562 
 
-1.58 0.0178 
 
FBXW11 -1.14 0.7622 
 
1.22 0.1546 
 
FZD4 -1.17 0.8080 
 
1.57 0.0471 
 
AES -1.24 0.6211 
 
-1.18 0.0978 
 
WISP1 -1.30 0.7465 
 
2.57 0.0522 
 
FZD5 -1.34 0.5244 
 
-3.89 0.0264 
 
FZD6 -1.40 0.4451 
 
-4.53 0.0157 
 
DIXDC1 -1.46 0.5816 
 
-1.67 0.1018 
 
SLC9A3R1 -1.65 0.1151 
 
-3.08 0.0255 
 
FZD1 -1.76 0.3368 
 
-2.64 0.0739 
 
DVL2 -1.76 0.2626 
 
-3.14 0.0115 
 
Canonical and Non-canonical Wnts 
WNT1 3.08 0.2452 
 
409.38 0.0062 
 
WNT5A 2.72 0.2550 
 
1.79 0.1554 
 
WNT9A 2.23 0.2857 
 
9.79 0.0029 
 
FGF4 2.02 0.6038 
 
30.40 0.0423 
 
WNT11 1.77 0.6048 
 
5.36 0.0487 
 
WNT7B 1.69 0.3979 
 
-2.42 0.2114 
 
WNT2 1.54 0.6437 
 
-3.96 0.1880 
 
WNT8A 1.50 0.6616 
 
3.35 0.0509 
 
WNT2B 1.47 0.6071 
 
-4.66 0.1040 
 
WNT16 1.11 0.9023 
 
1.47 0.0341 
 
WNT3 1.04 0.9537 
 
-1.14 0.3081 
 
WNT7A -1.02 0.9895 
 
1.09 0.8917 
 
WNT4 -1.03 0.9638 
 
-2.33 0.0426 
 
WNT5B -1.21 0.7780 
 
-6.68 0.0099 
 
WNT10A -1.47 0.6703 
 
-1.61 0.5156 
 
WNT6 -1.56 0.6703 
 
-2.19 0.0136 
 
WNT3A -1.83 0.4476 
 
-4.63 0.0178 
 
Protein Modification Factors 
CTBP2 1.30 0.8733 
 
-1.01 0.9799 
 
CSNK1G1 1.24 0.6062 
 
1.25 0.3025 
 
CTBP1 -1.05 0.8733 
 
1.49 0.0504 
 
FBXW2 -1.09 0.8410 
 
-1.84 0.0410 
 
LRP6 -1.15 0.7569 
 
-1.05 0.8358 
 
FBXW4 -1.18  
0.7499 
 
1.39 0.0135 
 
CSNK2A1 -1.23 0.6434 
 
1.56 0.0071 
 
CSNK1D -1.31 0.3662 
 
1.04 0.7817 
 
BTRC -1.42 0.3978 
 
-1.41 0.0515 
 
NLK -1.43 0.3654 
 
-1.19 0.3083 
 
FRAT1 -2.11 0.1760 
 
-1.33 0.2520 
 
RHOU -2.12 0.1074 
 
-1.41 0.1270 
 
Wnt Pathway Antagonists 
SFRP4 4.30 0.2124 
 
-1.52 0.6190 
 
FSHB 2.37 0.1928 
 
3.76 0.3647 
 
AXIN1 1.78 0.2785 
 
1.95 0.2671 
 
CXXC4 1.54 0.5992 
 
-3.07 0.1550 
 
DKK1 1.54 0.6974 
 
3.96 0.0543 
 
PPP2R1A 1.27 0.5708 
 
1.82 0.0666 
 
GSK3B 1.12 0.7705 
 
1.87 0.0042 
 
BCL9 1.11 0.7665 
 
-2.73 0.0207 
 
FRZB 1.06 0.9532 
 
-2.39 0.3826 
 
PORCN 1.04 0.9458 
 
1.03 0.9501 
 
SFRP1 -1.04 0.9655 
 
-8.62 0.0003 
 
GSK3A -1.24 0.5604 
 
1.10 0.5060 
 
DAAM1 -1.27 0.5407 
 
-2.70 0.0053 
 
PPP2CA -1.39 0.4604 
 
1.38 0.0954 
 
NKD1 -1.45 0.6823 
 
-2.87 0.0947 
 
KREMEN1 -1.51 0.5416 
 
1.38 0.1835 
 
TCF7L1 -1.60 0.5948 
 
-1.43 0.1828 
 
CTNNBIP1 -2.06 0.0908 
 
-3.32 0.0326 
 
WIF1 -17.89 0.0039 
 
-4.68 0.0182 
 
Supplementary Table 1: Wnt pathway array analysis of clinical samples. Fold difference 
values for each gene were calculated for primary tumor vs normal prostate and bone 
metastasis vs normal prostate comparisons. Genes are grouped in categories defined by 
manufacturer. RNA from fresh frozen clinical samples was analyzed using the SA 
Bioscience RT2 Profiler PCR Wnt Pathway array system and assessed statistically using 
one-way ANOVA followed by Student’s T-test using the analysis template provided by 
SA Bioscience, as detailed in methods. Sample n = 2 normal prostate, 9 primary CaP 
tumor and 1 CaP metastasis to bone. P values <0.05 were considered to indicate 
significant differences from normal prostate values. 
 
 
Figure S.1: Knockdown of individual PITX2 isoforms by shRNAs employed in this 
study. Specific FLAG-tagged PITX2 isoforms were over-expressed in PC-3 cells by 
transient transfection without or with individual SH3, SH4 or NC plasmid. (A) PITX2A + 
shRNA, (B) PITX2B + shRNA, (C) PITX2C + shRNA. Protein expression of the FLAG 
epitope tag was assessed by Western blot, with quantification of specific signal intensity 
normalized to ! tubulin signal. Knockdown efficacy was normalized to expression of 
each PITX2 isoform co-transfected with NC (zero value). Effective and consistent 
knockdown of all three PITX2 isoforms was observed with over expression of SH3 or 
SH4.  
 
Method for assessment of shRNA efficacy. 
 
To verify the functionality of shRNA plasmids (SA Bioscience), PC-3 cells were 
transiently co-transfected with each individual PITX2 isoform clone (0.5µg) along with 
each individual shRNA clone (0.5µg). Whole cell lysates were resolved by SDS-PAGE 
and transferred to Immobilon-FL (Millipore). Primary antibody was anti-DYKDDDDK 
FLAG (Cell Signaling Technology) antibody (1:5000) or monoclonal anti-!-tubulin 
(1:5000). Secondary fluorescent conjugated antibodies (Rockland) was diluted in 
PBS:Odyssey blocking buffer (1:10000). Membranes were scanned and analyzed using 
the LI-COR Odyssey Infrared Imaging System and proprietary software.  
 
